Novartis cholesterol drug setback raises stakes for Amgen, Eli Lilly
Novartis' failure in reducing Lp(a) levels intensifies competition among drugmakers racing to prove lower cholesterol correlates with fewer cardiovascular events.
Novartis has experienced a failure in its cholesterol drug development, according to reports. The setback has significant implications for the multibillion-dollar pharmaceutical race to develop treatments targeting Lp(a), a lipoprotein linked to cardiovascular risk.
The failure raises the stakes for competing drugmakers Amgen and Eli Lilly, which are both pursuing strategies to lower Lp(a) levels and establish clinical evidence that such reductions result in fewer heart attacks and strokes.
Sources
- Cholesterol drug setback casts doubt over multibillion-dollar race — CNBC — Top News
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Related articles
Thousands of Eligible Families Missing Out on NHS Food Support, Figures Show
New data cited by the BBC indicates that as few as 64% of families entitled to NHS money for milk, fruit and vegetables are actually claiming it.
Study Warns Against Sleeping More Than 9 Hours Daily
Long-term research links excessive sleep to higher mortality rates compared to 7-8 hours.
From Mumbling to Ringing: Hidden Signs That May Indicate Hearing Loss
A report identifies a range of daily signals that may be early indicators of declining hearing and warrant attention and medical evaluation
Three men charged in domestic violence murders as three women killed in NSW within 12 hours
A woman in her 90s in Bondi Beach, a 23-year-old in Wagga Wagga, and a woman in her 70s in Mole River died in separate incidents on Saturday.
Australia's life expectancy forecast to reach 89 for women, 86 for men by 2066
Treasury's intergenerational report projects Australians will live significantly longer over the next four decades.
DR Congo rolls out Ebola vaccine for health workers as death toll rises
The country has begun vaccinating 50,000 frontline health workers against a different Ebola strain while 20,000 are enrolled in a clinical trial.
Comments
Loading comments…